5-羟基戊酰胺 | 29686-12-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 5-羟基戊酰胺
• 英文名称: 5-pentanolide
• 英文别名: 5-hydroxy-valeric acid amide；5-Hydroxy-valeriansaeure-amid；5-Hydroxy-valeramid；5-hydroxy-pentanamide；4-hydroxybutylformamide；5-hydroxy-valeramide；Pentanamide, 5-hydroxy-；5-hydroxypentanamide
• CAS: 29686-12-2
• 化学式: C₅H₁₁NO₂
• 分子量: 117.148
• InChiKey: UYOWQFWKDDJSLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-羟基戊酰胺 在 silica gel 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以80%的产率得到戊二酰亚胺
  参考文献：
  名称：

  A Mild and Facile Synthesis of Cyclic Imides using Pyridinium Chlorochromate

  摘要：

  本文介绍了一种温和、简便的环状亚胺合成方法。这些化合物被广泛用于合成新型医用、聚合、光子和电子材料。与传统合成方法相比，该方法具有条件温和、操作简单和成本低廉等优点。

  DOI：

  10.3184/174751911x13202290249578
• 作为产物：
  描述：

  delta-戊内酯 在 氨 作用下， 以 甲醇 为溶剂， 生成 5-羟基戊酰胺
  参考文献：
  名称：

  A Mild and Facile Synthesis of Cyclic Imides using Pyridinium Chlorochromate

  摘要：

  本文介绍了一种温和、简便的环状亚胺合成方法。这些化合物被广泛用于合成新型医用、聚合、光子和电子材料。与传统合成方法相比，该方法具有条件温和、操作简单和成本低廉等优点。

  DOI：

  10.3184/174751911x13202290249578

文献信息

• A mild hydration of nitriles into amides
  作者：P. Breuilles、R. Leclerc、D. Uguen

  DOI：10.1016/s0040-4039(00)76229-0

  日期：1994.2

  Stirring mixtures of β-hydroxynitriles with manganese dioxide, deposited onto silica gel for a few days at room temperature resulted in the formation of the corresponding amides in fair to good yields. The unprecedented conversion of 3-hydroxyglutarodinitrile into the corresponding monoamide has been performed by this methodology.

  在室温下将几天内沉积在硅胶上的β-羟基腈与二氧化锰的混合物进行搅拌，导致以适当的收率形成了相应的酰胺。通过这种方法已经完成了3-羟基戊二腈向相应的单酰胺的前所未有的转化。
• [EN] THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] COMPOSES DE THIAZOLE EN TANT QUE DERIVES D'ANTAGONISTES DES RECEPTEURS DE L'INTEGRINE
  申请人：PHARMACIA CORP

  公开号：WO2004058760A1

  公开（公告）日：2004-07-15

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the ανβ3 and/or the ανβ5 integrin without significantly inhibiting the ανβ6 integrin.

  本发明涉及包含式(I)化合物的药物组合物，以及选择性抑制或拮抗ανβ3和/或ανβ5整合素而不显著抑制ανβ6整合素的方法。
• Pyridine-3-carboxamide derivatives as CB1 inverse agonists
  申请人：Hebeisen Paul

  公开号：US20060229326A1

  公开（公告）日：2006-10-12

  The present invention relates to compounds of the formula wherein X and R 1 to R 8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.

  本发明涉及以下式子的化合物：其中X和R1至R8如描述和权利要求中所定义，并且其药学上可接受的盐。该化合物可用于治疗和/或预防与CB1受体调节有关的疾病，如肥胖症。
• Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.
  作者：Feng Liu、Xin Chen、Abdellah Allali-Hassani、Amy M. Quinn、Tim J. Wigle、Gregory A. Wasney、Aiping Dong、Guillermo Senisterra、Irene Chau、Alena Siarheyeva、Jacqueline L. Norris、Dmitri B. Kireev、Ajit Jadhav、J. Martin Herold、William P. Janzen、Cheryl H. Arrowsmith、Stephen V. Frye、Peter J. Brown、Anton Simeonov、Masoud Vedadi、Jian Jin

  DOI：10.1021/jm100478y

  日期：2010.8.12

  Protein lysine methyltransferase G9a, which catalyzes methylation of lysine 9 of histone H3 (H3K9) and lysine 373 (K373) of p53, is overexpressed in human cancers. Genetic knockdown of G9a inhibits cancer cell growth, and the dimethylation of p53 K373 results in the inactivation of p53. Initial SAR exploration of the 2,4-diamino-6,7-dimethoxyquinazoline template represented by 3a (BIX01294), a selective small molecule inhibitor of G9a and GLP, led to the discovery of 10 (UNC0224) as a potent G9a inhibitor with excellent selectivity. A high resolution X-ray crystal structure of the G9a-10 complex, the first cocrystal structure of G9a with a small molecule inhibitor, was obtained. On the basis of the structural insights revealed by this cocrystal structure, optimization of the 7-dimethylaminopropoxy side chain of 10 resulted in the discovery of 29 (UNC0321) (Morrison K(i) = 63 pM), which is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date.
• Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties
  作者：John A. Wendt、Hongwei Wu、Heather G. Stenmark、Mark L. Boys、Victoria L. Downs、Thomas D. Penning、Barbara B. Chen、Yaping Wang、Tiffany Duffin、Mary Beth Finn、Jeffery L. Keene、V. Wayne Engleman、Sandra K. Freeman、Melanie L. Hanneke、Kristen E. Shannon、Maureen A. Nickols、Christina N. Steininger、Marissa Westlin、Jon A. Klover、William Westlin、G. Allen Nickols、Mark A. Russell

  DOI：10.1016/j.bmcl.2005.11.017

  日期：2006.2

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

表征谱图